Autopsy report · NCT03988842

Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism

“COVID-19 pandemic”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 8 months before it stopped.
• 4 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Victor Tapson, MD

Sponsor type

University, hospital or other

Conditions

Pulmonary Embolism With Acute Cor Pulmonale; Pulmonary Embolism; Pulmonary Embolism With Pulmonary Infarction; Pulmonary Embolism Subacute Massive; Right Ventricular Dysfunction; Right Ventricular Failure

Interventions

Alteplase; Unfractionated heparin; Placebo; Apixaban

Participants

4

Sites

1

Countries

United States

Trials that died the same way

• Resting Energy Expenditure in Patients With OHS Treated With Long-term NIV
  “COVID pandemic” (90% match in meaning)
• Microbiome Alterations in IL10RA-deficient Patients After HSCT
  “COVID-19” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.